Next-generation cancer tests are being developed here in Houston, and the HBJ pulled back the curtain on how one partnership ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites ...

Tempus and NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will support NYU Langone ...

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple ...

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...

EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...

Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...